Trump Secures Second Deal for Favored Nation Pricing for U.S. Patients
President Donald J. Trump has secured a significant deal with AstraZeneca to implement most-favored-nation (MFN) pricing for prescription drugs. This agreement aims to ensure that American patients benefit from lower drug prices comparable to those in other developed countries.
Details of the Agreement
The new agreement allows all State Medicaid programs to access MFN pricing for AstraZeneca products. This initiative is expected to generate savings amounting to hundreds of millions of dollars.
- The MFN pricing will cover all new innovative medicines released by AstraZeneca.
- AstraZeneca must also return increased foreign revenue generated under U.S. trade policies back to American patients.
- This deal will require AstraZeneca to sell their drugs at considerable discounts directly to American consumers.
Cost Savings for Patients
With this initiative, approximately 9 million American patients who use AstraZeneca medications will see reduced costs. Key statistics include:
- 25 million Americans suffering from asthma may benefit.
- 16 million Americans with chronic obstructive pulmonary disease (COPD) stand to gain.
Specific drug price reductions include:
| Medication | Discount Off Deal Price |
|---|---|
| BEVESPI AEROSPHERE (COPD) | 654% |
| BREZTRI AEROSPHERE (COPD) | 98% |
| AIRSUPRA (Asthma) | 96% |
Investment in U.S. Manufacturing
AstraZeneca has committed to a $50 billion investment in U.S. manufacturing and research by the year 2030. This includes a new facility in Charlottesville, Virginia, dedicated to producing advanced pharmaceutical ingredients. The project is expected to create 3,600 skilled jobs.
Addressing Global Pricing Disparities
President Trump’s administration is focused on correcting disparities in drug pricing between the U.S. and other countries. Research indicates that Americans pay over three times more for brand-name drugs compared to other high-income nations, even after considering discounts. This policy aims to reduce the burden on American taxpayers, who currently subsidize drug manufacturers’ profits significantly.
Commitment to American Patients
President Trump remains devoted to ensuring that American citizens receive fair pricing for prescription medications. His administration has taken multiple steps, including the signing of an Executive Order on May 12, 2025, aimed at aligning U.S. drug prices with those of other nations. The deal with AstraZeneca follows a similar agreement reached with Pfizer.
Through these efforts, President Trump aims to protect American consumers from excessive pricing and make prescription medications more affordable.
